Geode Capital Management, LLC Aptevo Therapeutics Inc. Transaction History

Geode Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.17 - $0.38 $5,466 - $12,218	-32,154 Reduced 42.67%	43,201 $7,000
Q3 2023 Nov 13, 2023	BUY	$0.31 - $1.78 $6,984 - $40,103	22,530 Added 42.65%	75,355 $24,000
Q4 2022 Feb 13, 2023	SELL	$2.0 - $138.16 $272 - $18,789	-136 Reduced 0.26%	52,825 $122,000
Q2 2022 Aug 12, 2022	BUY	$3.26 - $6.3 $762 - $1,474	234 Added 0.44%	52,961 $189,000
Q1 2022 May 13, 2022	BUY	$4.48 - $8.42 $57,881 - $108,786	12,920 Added 32.46%	52,727 $309,000
Q4 2021 Feb 11, 2022	SELL	$6.48 - $17.49 $758 - $2,046	-117 Reduced 0.29%	39,807 $313,000
Q3 2021 Nov 12, 2021	BUY	$15.01 - $22.16 $15,115 - $22,315	1,007 Added 2.59%	39,924 $616,000
Q2 2021 Aug 13, 2021	BUY	$21.85 - $30.0 $68,936 - $94,650	3,155 Added 8.82%	38,917 $872,000
Q1 2021 May 12, 2021	BUY	$27.86 - $40.59 $210,343 - $306,454	7,550 Added 26.76%	35,762 $1.09 Million
Q4 2020 Feb 12, 2021	BUY	$6.21 - $48.36 $108,718 - $846,638	17,507 Added 163.54%	28,212 $1.03 Million
Q2 2020 Aug 13, 2020	BUY	$3.11 - $9.27 $1,231 - $3,670	396 Added 3.84%	10,705 $89,000
Q1 2020 May 14, 2020	BUY	$3.29 - $9.73 $33,916 - $100,306	10,309 New	10,309 $38,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.5M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.